Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
NCT ID: NCT00048945
Last Updated: 2017-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
820 participants
INTERVENTIONAL
2002-01-31
2004-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
NCT00487747
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
NCT02604823
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
NCT01011738
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).
NCT00435825
A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
NCT00940485
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEGASYS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not pregnant
Exclusion Criteria
* Other hepatitis infections
* Severe liver disease
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scottsdale, Arizona, United States
Downey, California, United States
Los Angeles, California, United States
Pasadena, California, United States
San Francisco, California, United States
Atlanta, Georgia, United States
Honolulu, Hawaii, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Lincoln, Nebraska, United States
Chapel Hill, North Carolina, United States
Cedar Creek, Texas, United States
Salt Lake City, Utah, United States
Seattle, Washington, United States
Concord, , Australia
Herston, , Australia
Campinas, , Brazil
Porto Alegre, , Brazil
Salvador, , Brazil
São Paulo, , Brazil
Calgary, Alberta, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Beijing, , China
Beijing, , China
Beijing, , China
Beijing, , China
Beijing, , China
Chengdu, , China
Chongqing, , China
Guangzhou, , China
Guangzhou, , China
Hangzhou, , China
Hong Kong, , China
Shanghai, , China
Shanghai, , China
Shanghai, , China
Clichy, , France
Lyon, , France
Berlin, , Germany
Bochum, , Germany
Cologne, , Germany
Düsseldorf, , Germany
Hanover, , Germany
München, , Germany
Haifa, , Israel
Petah Tikva, , Israel
Tel Aviv, , Israel
Otahuhu, , New Zealand
Bialystok, , Poland
Bydgoszcz, , Poland
Warsaw, , Poland
Santurce, , Puerto Rico
Singapore, , Singapore
Singapore, , Singapore
Singapore, , Singapore
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Basel, , Switzerland
Kaohsiung City, , Taiwan
Kwei Shan, , Taiwan
Tainan City, , Taiwan
Taipei, , Taiwan
Taipei, , Taiwan
Taipei, , Taiwan
Bangkok, , Thailand
Bangkok, , Thailand
Bangkok, , Thailand
Chiang Mai, , Thailand
Songkhla, , Thailand
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WV16240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.